Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Therapeutic peptides for cerebrovascular diseases

A technology for cerebrovascular diseases and uses, applied in the field of treating or improving cerebrovascular diseases of subjects

Active Publication Date: 2018-03-27
PRIME BIO DRUG DEV LTD
View PDF4 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the active ingredient of Enzaiq that contributes to this effect has not been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Therapeutic peptides for cerebrovascular diseases
  • Therapeutic peptides for cerebrovascular diseases
  • Therapeutic peptides for cerebrovascular diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0041] Example 1 Separation and Characterization of Active Components in Enzaiq® (AGC)

[0042] 1.1. Separation and structure analysis of the active ingredient of Enzai

[0043] 1.1.1. Materials and methods

[0044] 1) Sample preparation

[0045] Approximately 200 μL of the bioagent mixture produced from rabbit skins with inflammation induced by inoculation with vaccinia virus was dried in a vacuum centrifuge.

[0046] The lyophilized material was reconstituted with 100 μL of 0.5 M ammonium bicarbonate buffer (pH 8.5) containing 8 M urea and 0.5 M dithiothreitol (DTT) at 37°C for 1 hr, when 10 μL of 0.5 M iodoacetamide was added (IAM) was alkylated for an additional 2 hr at 4°C in the dark, then diluted with 400 μL ammonium bicarbonate. Subsequently, the resulting solution was then digested with 0.2 μg trypsin at 37°C for 18 h, and then treated with 10% trifluoroacetic acid (TFA) / H 2 O Acidify the trypsin-digested solution to a pH value of 3.0. After the reaction, the f...

Embodiment 2

[0070] 2.1 Protective effect on PC12 cells treated with hydrogen peroxide

[0071] 2.1.1 Materials and methods

[0072] 1) When exposed to H 2 o 2 Role of isolated peptides or AGC in survival of PC12 cells

[0073] PC12 cells, derived from a pheochromocytoma of the rat adrenal medulla showing some features of ganglion cells, were obtained from the Chinese Academy of Medical Sciences, Beijing, China. To check when exposed to H 2 o 2 When the cells survived, PC12 cells were grown to confluence in 96-well plates, and the medium was replaced with 200 µM H 2 o 2 (final volume 100 µl) in serum-free medium for 24 h. In treated cells, exposure to H 2 o 2 The isolated peptide or AGC was provided to the wells for 1 h. After 24 h of incubation, 100 µL of MTT (final concentration 0.5 mg / ml) was added and incubated for an additional 4 h, followed by assessment of cell viability by absorbance at 540 nm in a Fluostar microplate reader (BMG, Germany).

[0074] 2) Statistical analy...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides a method for treating or ameliorating cerebrovascular diseases in a subject by using peptides isolated from extracts from rabbit skin inflamed by vaccinia virus. The present invention also provides a peptide comprising an amino acid sequence having at least 70% identity to SEQ ID NO:1, or variants, mutants, derivatives, or fragments thereof.

Description

field of invention [0001] The present invention relates to the treatment of cerebrovascular diseases. In particular, it relates to a method for treating or improving cerebrovascular disease in a subject by using a peptide isolated from an extract of vaccinia virus-inflamed rabbit skin. Background of the invention [0002] Cerebrovascular diseases are neurological impairments caused by abnormal blood supply to the local brain. Cerebrovascular disease is the top three cause of all death in most countries and can lead to brain damage in adults. Cerebrovascular disease is the leading cause of health-threatening health in middle-aged and older adults and the leading cause of death or disability in middle-aged and older adults in most countries. [0003] Stroke is one of acute cerebrovascular diseases, which is the third leading cause of death worldwide and induces the highest disability rate among various diseases. Cerebrovascular disease can seriously affect the quality of li...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/10A61P9/10C07K7/08C07H21/00C12N15/01A61K38/08
CPCC07H21/00C07K14/47A61K38/00A61P9/10A61K38/08A61K38/10C07K7/06C07K7/08
Inventor 林成龙
Owner PRIME BIO DRUG DEV LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com